Abstract
Immunotoxins (ITs) permit delivery of a therapy at the tumor site specifically. The use of ITs as therapy of patients with solid tumors presents problems which require unique solutions. These include stability in vivo, cellular heterogeneity, access to tumor, biodistribution, and the immune response to the immunoconjugate (Table 1). It is necessary to address some of these issues before contemplating entry into clinical trials, whereas others are more appropriately undertaken after clinical trials have been initiated, using the results of the clinical observations as a focus for planning improvements as part of a second generation effort. This involves both optimizing the administration of the currently available products and developing new, improved products.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Spitler, L.E. (1987) Phase I clinical trials with immunotoxins. In: Immunoconjugates: Antibody Conjugates in Radioimaging and Therapy of Cancer. C.-W. Vogel, ed. Oxford University Press, New York.
Eiklid, K., Olsnes, S., and Pihl, A. (1982) Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp. Cell Res. 126, 321–326.
Falini, B., and Taylor, C.R. (1983) New developments in immunoperoxidase techniques and their application. Arch. Pathol. Lab. Med. 107, 105–117.
Levy, J.A., Lee, H.M., Kawahata, R.T., and Spitler, L.E. (1984) Purification of monoclonal antibodies from mouse ascites eliminates contaminating infectious mouse type C viruses and nucleic acids. Clin. Exp. Immunol. 56, 114–120.
Balint, G.A. (1974) Ricin: The toxic protein of caster oil seeds. Toxicology 2, 77–102.
Jansen, F.K., Blythman, H.E., Carriere, D., Casillas, P., Gros, P., Laurent, J.C., Paolucci, F., Pau, B., Poncelet, P., Richer, G., Vidal, H., and Voisin, G.A. (1982) Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunol. Rev. 62, 185–216.
Mischak, R., and Stoudemier, J. (1987) Preclinical evaluation of monoclonal anitmelanoma antibody ricin A chain immunotoxin, manuscript in preparation.
Engelstad, B., Khentigan, A., del Rio, M., Rosendorf, L., Ramos, E., Reinhold, C., Hattner, R., Okerlund, M., Spitler, L., and Scannon, P. (1985) Initial clinical experience with intravenous and subcutaneous indium-111 antimelanoma monoclonal radioimmunoimaging. Radiology, 157, 98.
Spitler, L.E., del Rio, M., Khentigan, A., Wedel, N.I., Brophy, N.A., Miler, L.L., Harkonen, W.S., Rosendorf, L.L., Lee, H.M., Mischak, R.P., Kawahata, R.T., Stoudemire, J.B., Fradkin, L.B., Bautista, E.E., and Scannon, P.J. (1987) Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Research, 47, 1717–1723.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers
About this chapter
Cite this chapter
Spitler, L.E. (1988). Clinical studies: Solid tumors. In: Frankel, A.E. (eds) Immunotoxins. Cancer Treatment and Research, vol 37. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1083-9_28
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1083-9_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8419-2
Online ISBN: 978-1-4613-1083-9
eBook Packages: Springer Book Archive